Category Archives: Neurotechnology

Advertisement

Stryker Corporation (NYSE:SYK).

On June 30 analysts at Cantor Fitzgerald starting coverage on the stock giving it an initial rating of Neutral. On May 16, 2017 Goldman Sachs released its first research report on the stock by announcing an initial rating of Neutral.

In the market the company is trading down by -0.12% since yesterdays close of $138.36. Additionally the company recently declared a dividend which will be paid on Tuesday the 31st of October 2017. The dividend will be $0.425 per share for the quarter which is $1.70 annualized. The dividend yield will be $1.17. The ex-dividend date will be on Wednesday the 28th of June 2017.

The stock last traded at $138.19 which is marginally lower than the 50 day moving average of $144.81 and which is slightly above the 200 day moving average of $136.90. The 50 day moving average was down by -4.54% and the 200 day average went up $1.34 or +0.98%.

Stryker Corporation (Stryker), launched on February 20, 1946, is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Businesss segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The Businesss MedSurg segment consists of instruments, endoscopy, medical and sustainability products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products..

Stryker Corporations P/E ratio is 30.86 and market capitalization is 51.71B. As of the last earnings report the EPS was $4.48 and is projected to be $6.50 for the current year with 374,063,000 shares outstanding. Analysts expect next quarters EPS to be $1.95 with next years EPS anticipated to be $7.11.

Originally posted here:

Canaccord Genuity Keeps Rating And Raises Price Target On Stryker Corporation (SYK) - Modern Readers

New technologies may be on the way to better help doctors diagnose and treat patients with neurological diseases.

Researchers from the National Neuroscience Institute (NNI) and Nanyang Technological University, Singapore (NTU) have come together to develop several new technologies, including an artificial intelligence system that can accurately identify types of traumatic brain injuries from computed tomography (CT) scans.

Innovation occurs at intersections of disciplines, knowledge and expertise, associate professor Ng Wai Hoe, Medical Director of the National Neuroscience Institute, said in a statement. Doctors have a deep understanding of clinical needs from their everyday interactions with patients.

Our unique collaboration brings these medical needs to engineering laboratoriesan environment where imagination is encouraged in the form of technological advances and capabilities.

The researchers also plan to develop a computer algorithm for more precise identification of tissues during brain surgeries, which aim to restore the neurological functions of patients suffering from various conditions including Parkinsons disease.

A new fellowship programmanaged by NTUs Institute for Health Technologieswill see up to two neurosurgical residents at NNI work full-time with NTU professors on campus, with each resident receiving $100,000 to complete and commercialize these projects.

The program was designed to foster a relationship over the next three years between medical practitioners and engineers through annual fellowships and student attachment programs.

The rapidly ageing population will lead to a significant rise in neurological diseases globally, Hoe said. By harnessing the power of the human brain, neurotechnology can provide solutions to revolutionize the treatment of brain disorders.

This partnership has great potential to be an innovation launchpad for neurotechnology.

A student attachment program aimed at grooming multidisciplinary scientists will also be introduced, giving students an opportunity to widen their engineering knowledge into medical practice, gaining first-hand exposure to various aspects of clinical medicine by interacting with neurosurgeons.

Professor Lam Khin Yong, NTU's Chief of Staff and Vice President for Research, said the new technology will assist the next wave of doctors.

This collaboration creates a unique multidisciplinary research environment by integrating healthcare with both medical and engineering expertise from NTU's Lee Kong Chian School of Medicine and College of Engineering, Yong said in a statement. This will not only nurture next-generation doctors armed with a multidisciplinary skillset to meet Singapore's healthcare needs, but also enhance medical technologies to diagnose and treat neurological conditions more effectively.

In Switzerland, additional technological advancements are making an impact in the treatment of neurological disorders.

Researchers from the National Centre of Competence in Research Robotics at cole Polytechnique Fdrale de Lausanne (EPFL) and at the Lausanne University Hospital in Switzerland, have developed an algorithm to help those paralyzed by a neurological disorder or injury. The algorithm helps a robotic harness facilitate the movements of patients, enabling them to move naturally. This new technology could help patients regain their locomotor skills

A variety of neurological disorders including stroke, multiple sclerosis, cerebral palsy, can lead to paralysis. Currently, people with motor disabilities rehabilitate by walking on a treadmill with the upper torso being supported by an apparatus. However, this can be either too rigid or does not allow the patient to move naturally in all directions.

Locomotor rehabilitation requires helping the nervous system relearn the right movements, which is difficult due to the loss of muscle mass in patients, as well as train the neurological wiring that has forgotten correct posture.

The researchers designed the algorithm to overcome these obstacles. The robotic rehabilitation harness was tested on more than 30 patients and markedly and immediately improved the patients locomotor abilities.

The harnesscalled the smart walk assistis a body-weight support system that manages to resist the force of gravity and push the patient in a given direction to recreate a natural gait and movement that the patient needs in their everyday lives.

View original post here:

Technology Key to Fighting Neurological Disease - R & D Magazine

JoAnne Viviano The Columbus Dispatch @JoAnneViviano

A new pain pellet that scientists are developing in Columbus isabout half the size of a grain of rice, but researchers say it delivers a big dose of relief that could one day help fight the opioid epidemic.

The tiny rod holds a nonaddictive painkiller that doctors could insert in the lower back, much like an epidural, to give a patient a break from chronic or acute pain, said Dr. Ali Rezai, director of the Neurological Institute at Ohio State University's Wexner Medical Center. He would not reveal the painkiller, saying only that it is a drug that already has beenused successfully as a cardiovascular medication.

Goals includegiving physicians an alternative to the opioid-based pain medications that have led to addiction.

"We want to look at the opioid crisis," Rezai said. "We want to stop it at its root."

Supporters have formed a company, Sollis Therapeutics, to create the product and are now raising funds, said Dr. Greg Fiore, Sollis' chief executive officer. Fiore hails from Boston and is the founder of Fiore Healthcare Advisors, a scientific consulting firm. Rezai serves as scientific adviser to Sollis.

>> Join the conversation at Facebook.com/columbusdispatchand connect with us on Twitter @DispatchAlerts

A small trial of 55 people with sciatica pain in the lower back and legs showed that the pellet stopped pain for up to one year and was safe and easy to use,Fiore said. Researchers will next seek to perform a large clinical trial, hoping toconfirm effectiveness and safety. The trial will involve a broader group of peopleculled from pain centers across Ohio.

If efficacy and safety are proved, researchers would seek approval for the pellet from the U.S. Food and Drug Administration. They hope to have the pellet in use within four or five years.

Sollis, headquartered in the University District, is the second company to be formed by the Neurotechnology Innovations Translator, which is funded by the Ohio Third Frontier Program. Both seek to move ideas from the lab to the marketplace.

Opioids are commonly used to treat chronic pain,Rezai said.

But the highly addictive nature of the medications, Fiore said, is a reason to find alternatives. Someone who takes opioids for a single day, for example,has a 6 percent chance of being addicted a year later.

"It's really important to avoid starting, even for legitimate conditions," he said. "It confers an increased risk for not being able to come off these drugs."

Along with medications, 11 million steroid injections are given each year to treat neck and back pain in the United States, Rezai said.Such injections might not work and, when they do, relief doesn'tlast long.

He wanted to bring the project to Ohio, and hopes are to eventually manufacture the pellets here.

"It's one of the ground zero states for the opioid crisis," Rezai said. "This is a big problem; it's just spiraling, so we want to find solutions quickly."

jviviano@dispatch.com

@JoAnneViviano

See the original post here:

Could this back-pain device end need for opioids? - The Columbus Dispatch

Elon Musk wants to get inside your head. In April, the Silicon Valley billionaire announced plans to launch Neuralinka company dedicated to developing a brain-to-machine interface to cure brain ailments like paralysis and memory problems and help people compete with robots when the artificial intelligence revolution makes human brains obsolete. Musk says this will be accomplished by implanting tiny electrodes into the brainallowing for things like downloading and uploading memory and casual brain-to-brain communication.

Leaders in the neurotechnology field welcome Musks arrival, while neuroethicists and others urge caution. The endeavor may sound like science fiction, but its feasible, says Timothy Deer, president of the International Neuromodulation Society, a nonprofit group of researchers and developers dedicated to using spinal cord stimulation to treat neurological pain. The cochlear implant was invented 20 years ago, and with electricity and the right frequencies targeting the brain, it allows people to hear, he says. That sounded impossible back then. And great gains require great brains, Deer says. Ben Franklin didnt know how to harness electricity, but he and others knew it was the key to something. Now, we know how to use electricity in very specific ways. Its exciting to see how Mr. Musk might change how we think.

Humans have been trying to mess with their brain waves to solve diseases since ancient times: The Romans and Greeks used to put electric fish on top of their heads to relieve pain, says Ana Maiques, CEO of Neuroelectrics, a company that develops noninvasive wireless brain monitoring and stimulation technologies.

Tech & Science Emails and Alerts - Get the best of Newsweek Tech & Science delivered to your inbox

Elon Musk, chairman and chief executive officer of Tesla Motors Inc., gestures as he speaks during a news conference in Fremont, California, on September 29, 2015. David Paul Morris/Bloomberg/Getty

Maiques is happy Musk has entered the neurotech field. With new technologies, including artificial intelligence, there is a lot of room for startups and new companies, she says.

Jennifer French, co-founder and executive director of Neurotech Network, a nonprofit that advocates for and educates the public about implantable technology, says investments in neuroscience and neurotechnology from the Brain Research Through Advancing Innovative Neurotechnologies Initiative started by the Obama administration have been critical in exploring the brains mysteries.

Zack Lynch, founder of Neurotechnology Industry Organization, a global trade association representing companies involved in neuroscience and brain research, says, The [human] brain is the most complicated organ on the planet. The neurotechnology industry produces $165 billion in yearly revenue, he says, but 90 percent of that revenue comes from pharmaceuticals for neurological disorders like Lou Gehrig's disease, or amyotrophic lateral sclerosis, as well as post-traumatic stress disorder and depression. Annual revenue from neurological devices is about $10 billion.

If Musk is successful, he will run into a swamp of ethical issues. Neuroscience raises questions about technology, art, entertainment, warfare, religion and what it means to be human, Lynch says. And these considerations will be difficult to address in the short term, says Peter Reiner, professor and co-founder of the National Core for Neuroethics. Most important is privacy of thought. When a computer is hooked up to me and knows what Im thinking, that becomes a very challenging area to navigate. Another issue is what Reiner calls reason bypassing. If a device can influence your brain without you perceiving it, are you really making your decisions? He believes society already faces these questions with smartphones: Advertisers are collecting information about users based on their browsing habits and then using that data to try to change their behavior.

Daniel Wilson, a best-selling author and robotics engineer, considers these ethical issues in his novel Amped, which predicts that neurotechnology will cure people with mental disabilities and eventually help them leapfrog beyond human ability. The amplified humans known as amps are then discriminated against because the public fears their abilities.

Wilson believes brain-to-machine interfaces will become common, but that they will not diminish the humanity of their users. People often look at human creations, and we call them unnatural, Wilson says. But from my perspective, theres nothing more natural than a human being creating a tool. Birds nests or anything animals do instinctively always seems natural, but we consider it unnatural when a human uses a tool. Thats the most natural thing that a human can do. To put that tool in our bodies is a completely natural extension of what weve been doing for millennia.

Excerpt from:

In the Future, Humans Will Use Brain to Brain Communication and Download Their Memories If Elon Musk Has His Way - Newsweek

Neurotechnology startup Rythm is building Morpheo, an open-source and secure initiative to help develop machine learning models for automatic and predictive diagnosis of sleep disorders.Morpheo will explore and provide sleep clinicians with a free online software that will automatically analyze sleep patterns and help improve and speed diagnosis related to sleep. Morpheo will also enable software developers and machine learning experts as they create models for the diagnosis of other illnesses. Rythm jointly announced Morpheo with cole Polytechnique and the Universit Paris Descartes with 5 million in funding from the French government and BPI, a French investment bank.

A collaborative project, Morpheo brings patients, medical doctors, sleep experts, academic researchers, data scientists, web developers, and cryptologists together to aggregate and organize sleep data on an unprecedented scale. Through sophisticated artificial intelligence and blockchain technology, Morpheo helps visualize complex sleep data for clinicians and allows development of machine learning models on large medical datasets. All of the above is achieved while guaranteeing the privacy and security for all data owners.

Artificial intelligence, ever-increasing computational power, and unprecedented amounts of data are transforming the healthcare industry, says Hugo Mercier, CEO and co-founder at Rythm, in a release. We are leveraging these advancements to understand one of the most important areas of health: sleep. We created Morpheo to provide a research tool that will pave the way for preventive and predictive medicine, enabling clinicians to treat pathologies earlier, faster and cheaper, and even to detect them before they happen.

Once built and launched, Morpheo will be powered by a certified, open-source blockchain infrastructure that guarantees the privacy of data. Users cannot access each others data, and only limited, agreed upon machine learning algorithms can access the data for training. Using AI, Morpheo will integrate various sources of information, ranging from traditional medical polysomnography to sleep wearables (like the Dreem headband). With these datasets, Morpheo will identify patterns that characterize sleep pathologies and other related illnesses that are attributed to sleep data.

As Morpheos infrastructure is data and algorithm agnosticin the longer termits approach could be generalized to other healthcare possibilities and beyond. What makes Morpheo unique is its versatility in handling sensitive data to solve critical challenges across various fields that apply and benefit fromartificial intelligence.

See the original post here:

Open-source Morpheo Platform to Use Artificial Intelligence to Help Diagnose Sleep Disorders - Sleep Review

What We Should Know about Stryker's 2Q17 Earnings PART 1 OF 3

On July 27, 2017, Stryker (SYK) released its 2Q17 earnings. The company reported strong earnings and exceeded analysts expectations. However, on the day of the release, Stryker stock fell approximately 1.3% from the closing price of $145.70 on July 26, 2017. Notably, Stryker also raised its 2017 guidance during the 2Q17 earnings announcement.

Interested in SYK? Don't miss the next report.

Sign Up

Receive e-mail alerts for new research on SYK

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

In 2Q17, Stryker earned revenue of ~$3.0 billion. It registered strong growth of ~6.1% on a YoY (year-over-year) basis and exceeded analysts estimates of $2.98 billion in revenues.

The currency-neutral sales growth for the quarter came in at 6.9% on a YoY basis. The growth included a 0.20% acquisitions contribution and a negative pricing impact of around 1.5%. The companys organic revenue growth was thus around 6.7%. Strykers sales growth was driven by strong results across all three of its business segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The company continued to witness strong results in Canada and Europe led by its Transatlantic Operating Model (or TOM). For brief details on TOM, read How Stryker Plans to Capture the International Markets.

Organic sales growth of 6.7% for Strykers MedSurg segment was driven by strong instrument sales in the United States. Its Orthopaedics segment witnessed strong sales growth of 6.2%. Orthopaedics sales were driven by strong knee sales as well as strong trauma and extremities sales, led by the strong demand for Strykers 3D-printed products, including its Triathlon Knee and foot and ankle portfolio. Neurotechnology and Spine sales registered an organic growth of around 7.9%, which was mainly led by strong momentum across the companys neurotechnology portfolio. Spine sales continued to be impacted by supply issues in the United States

Sales in the United States rose approximately 7.2%, and international sales rose approximately5.5%. International sales witnessed strong contributions from Europe and Australia, while emerging markets continued to recover.

Strykers peers Zimmer Biomet Holdings (ZBH), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) earned revenues of about $1.9 billion, $5.0 billion, and $6.6 billion, respectively, for their recently ended quarters. For exposure to Strykers growth potential, you can invest in theiShares Core S&P 500 (IVV), which holds approximately 0.21% of its total holdings in SYK.

Read more from the original source:

Stryker Exceeded Analysts' Sales Estimates in 2Q17 - Market Realist

Mashable

Elon Musk talks of his life's 'highs' and 'lows' in a few painfully honest tweets Mashable As the CEO of automaker Tesla and private space transport company SpaceX, founder of neurotechnology company Neuralink and tunneling company Boring Company, and a key figure in AI non-profit OpenAI, Musk is obviously extremely busy. He's also a ... and more »

The rest is here:

Elon Musk talks of his life's 'highs' and 'lows' in a few painfully honest tweets - Mashable

Kevin co-founded the NIT with Dr. Rezai, after a distinguished career spanning over 20 years in venture capital and operating roles specializing in building medical device companies from concept to commercialization.Kevin brings an experienced and practiced hand to NIT, with roles spanning investment and board leadership, executive leadership, engineering, business development, and marketing.Prior to founding NIT, Kevin founded MentorCatalyst to pursue his passion for MedTech company-building and for working intimately with entrepreneurs with a craftsman-styled approach to working with startup MedTech teams, deeply engaging on a select few startup medical device companies, providing comprehensive leadership and guidance. Prior to NIT and MentorCatalyst, Kevin spent eleven years as a Managing Director at Versant Ventures where he focused on investing in and building early stage medical device companies, and participated in the Firms investments in over 100 healthcare companies across 3 different investment funds, with investment allocations of over $1.1 B in capital.Kevin currently serves, or has served, in board or advisory roles with companies which include Acclarent (acquired: Johnson & Johnson), Autonomic Technologies, Cereve, Eargo, LipoSonix (acquired: Medicis), Lutonix (acquired: Bard), Microfabrica, Neoguide Systems (acquired: Intuitive Surgical), Oculeve (acquired: Allergan), Respicardia, Rox Medical, Second Sight Medical (NASDAQ: EYES), St. Francis Medical (acquired: Kyphon), and The Innovation Factory.

Kevin previously held numerous operating leadership roles, including marketing and business development at Guidant Corporation, business development at Heartstream, and engineering development and management at Hughes Aircraft Company. Kevin holds both Bachelor's and Master's degrees in Mechanical Engineering, specializing in product design, as well as an MBA, all from Stanford University.

Read the original:

Team Neurotechnology Innovations Translator

Stryker Corporation (NYSE: SYK) and Uroplasty (NYSE:UPI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitabiliy and risk.

Profitability

This table compares Stryker Corporation and Uroplastys net margins, return on equity and return on assets.

Insider and Institutional Ownership

74.3% of Stryker Corporation shares are owned by institutional investors. 7.4% of Stryker Corporation shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Stryker Corporation and Uroplasty, as provided by MarketBeat.

Stryker Corporation presently has a consensus price target of $142.79, indicating a potential downside of 3.39%. Given Stryker Corporations higher probable upside, equities analysts clearly believe Stryker Corporation is more favorable than Uroplasty.

Dividends

Stryker Corporation pays an annual dividend of $1.70 per share and has a dividend yield of 1.2%. Uroplasty does not pay a dividend. Stryker Corporation pays out 37.9% of its earnings in the form of a dividend. Stryker Corporation has raised its dividend for 6 consecutive years.

Valuation & Earnings

This table compares Stryker Corporation and Uroplastys gross revenue, earnings per share (EPS) and valuation.

Stryker Corporation has higher revenue and earnings than Uroplasty.

Summary

Stryker Corporation beats Uroplasty on 10 of the 11 factors compared between the two stocks.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Companys segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Companys products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.

Uroplasty Company Profile

Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Companys products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

View post:

Stryker Corporation (NYSE:SYK) and Uroplasty (UPI) Financial Survey - Stock Observer

Tufts University is academic host and co-sponsor of the 2017 IEEE Midwest Circuits and Systems Symposium, to be held Aug. 6-9. The symposium will include oral and poster sessions, a student paper contest, tutorials by experts in circuits and systems topics, and special sessions. All areas of electronic circuits and systems will be covered, including the latest innovations in the field.

The three keynote speakers are Linton Salmon, Jesse Wheeler and Donhee Ham. Salmon, a program manager at the Defense Advanced Research Projects Agency, will give a keynote titled Microelectronics: Challenges and Opportunities on Aug. 7; Wheeler, the neurotechnology business lead at Draper Laboratory, will speak on Neurotechnology: Biomedical, Biomimetic, and Beyond on Aug. 8; and Ham, the Gordon McKay Professor of Applied Physics and Electrical Engineering at Harvard University, will speak on CMOS Electronics See Inside Biological Cellular Networks on Aug. 9.

Tufts Department of Electrical and Computer Engineering is well represented at the symposium. Associate Professor Valencia Joyner Koomson is technical program co-chair; Professor Sameer Sonkusale is publications co-chair; professor and department chair Eric Miller is advisory committee co-chair; and associate professors Mark Hempstead and Thomas Vandervelde are on the technical program committee.

Tufts undergraduate and graduates students will be presenters at the conference. Among them is Joel Dungan, a doctoral student in electrical and computer engineering, who has been selected as a finalist in the student paper contest.He will present research work on the development of a platform to study intercellular communication in non-neural cells as it relates to developmental biology and morphogenetic bioengineering. Co-authors on the paper are Koomson, biology postdoctoral scholar Juanita Mathews, and biology professor Michael Levin.

Other Tufts students presenting their research will be doctoral candidates Meera Punjiya,Yun Miao, Abigail Licht, John Chivers, Emily Carlson and Jun Jadormio, along with former undergraduate student Andrew Bourhis, E17.

For more information, and to register, go to the 2017 IEEE Midwest Circuits and Systems Symposium website.

Read this article:

Tufts Hosts Engineering Conference - Tufts Now